Pombiliti Atga
Pombiliti Atga ingredients
| Active ingredient | Strength |
|---|---|
| Cipaglucosidase Alfa | 105 mg/1 |
What Pombiliti Atga is used for
The FDA lists the approved uses on the official label (below). In the EU, cipaglucosidase alfa is approved as Pombiliti for:
Pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset Pompe disease (acid alpha-glucosidase [GAA] deficiency).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Pombiliti Atga
- Generic name
- Cipaglucosidase alfa-atga
- Made by
- AMICUS THERAPEUTICS US, LLC
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- Drug class
- Hydrolytic Lysosomal Glycogen-specific Enzyme
- FDA approval
- Biologic licence (BLA) BLA761204
- On the US market since
- 2023
Official information
- Pombiliti Atga prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Cipaglucosidase alfa-atga)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Pombiliti Atga?
Pombiliti Atga (Cipaglucosidase alfa-atga) is a specialist medicine made by AMICUS THERAPEUTICS US, LLC, approved by the US FDA.
What are the ingredients of Pombiliti Atga?
Pombiliti Atga contains Cipaglucosidase Alfa (105 mg/1).
Is Pombiliti Atga approved in Europe?
The same active substance is approved in the EU as Pombiliti.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA